114 related articles for article (PubMed ID: 30150405)
1. Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma.
Sonntag R; Giebeler N; Nevzorova YA; Bangen JM; Fahrenkamp D; Lambertz D; Haas U; Hu W; Gassler N; Cubero FJ; Müller-Newen G; Abdallah AT; Weiskirchen R; Ticconi F; Costa IG; Barbacid M; Trautwein C; Liedtke C
Proc Natl Acad Sci U S A; 2018 Sep; 115(37):9282-9287. PubMed ID: 30150405
[TBL] [Abstract][Full Text] [Related]
2. Association of germline variation in CCNE1 and CDK2 with breast cancer risk, progression and survival among Chinese Han women.
Han JY; Wang H; Xie YT; Li Y; Zheng LY; Ruan Y; Song AP; Tian XX; Fang WG
PLoS One; 2012; 7(11):e49296. PubMed ID: 23185313
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of the 19q12 amplicon in grade III breast cancers.
Natrajan R; Mackay A; Wilkerson PM; Lambros MB; Wetterskog D; Arnedos M; Shiu KK; Geyer FC; Langerød A; Kreike B; Reyal F; Horlings HM; van de Vijver MJ; Palacios J; Weigelt B; Reis-Filho JS
Breast Cancer Res; 2012 Mar; 14(2):R53. PubMed ID: 22433433
[TBL] [Abstract][Full Text] [Related]
4. Cyclin E/CDK2: DNA Replication, Replication Stress and Genomic Instability.
Fagundes R; Teixeira LK
Front Cell Dev Biol; 2021; 9():774845. PubMed ID: 34901021
[TBL] [Abstract][Full Text] [Related]
5. Pyruvate Dehydrogenase Kinase 4 Deficiency Results in Expedited Cellular Proliferation through E2F1-Mediated Increase of Cyclins.
Choiniere J; Wu J; Wang L
Mol Pharmacol; 2017 Mar; 91(3):189-196. PubMed ID: 28003426
[TBL] [Abstract][Full Text] [Related]
6. Daidzein and Chicory Extract Arrest the Cell Cycle
Abdel-Hamid NM; Zakaria S; Nawaya RA; Eldomany RA; El-Shishtawy MM
Recent Pat Anticancer Drug Discov; 2022; 18(2):187-199. PubMed ID: 35319392
[TBL] [Abstract][Full Text] [Related]
7. Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells.
Parisi T; Beck AR; Rougier N; McNeil T; Lucian L; Werb Z; Amati B
EMBO J; 2003 Sep; 22(18):4794-803. PubMed ID: 12970191
[TBL] [Abstract][Full Text] [Related]
8. Expression of cyclins E1 and E2 during mouse development and in neoplasia.
Geng Y; Yu Q; Whoriskey W; Dick F; Tsai KY; Ford HL; Biswas DK; Pardee AB; Amati B; Jacks T; Richardson A; Dyson N; Sicinski P
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13138-43. PubMed ID: 11687642
[TBL] [Abstract][Full Text] [Related]
9. The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease.
Fu YP; Kohaar I; Moore LE; Lenz P; Figueroa JD; Tang W; Porter-Gill P; Chatterjee N; Scott-Johnson A; Garcia-Closas M; Muchmore B; Baris D; Paquin A; Ylaya K; Schwenn M; Apolo AB; Karagas MR; Tarway M; Johnson A; Mumy A; Schned A; Guedez L; Jones MA; Kida M; Hosain GM; Malats N; Kogevinas M; Tardon A; Serra C; Carrato A; Garcia-Closas R; Lloreta J; Wu X; Purdue M; Andriole GL; Grubb RL; Black A; Landi MT; Caporaso NE; Vineis P; Siddiq A; Bueno-de-Mesquita HB; Trichopoulos D; Ljungberg B; Severi G; Weiderpass E; Krogh V; Dorronsoro M; Travis RC; Tjønneland A; Brennan P; Chang-Claude J; Riboli E; Prescott J; Chen C; De Vivo I; Govannucci E; Hunter D; Kraft P; Lindstrom S; Gapstur SM; Jacobs EJ; Diver WR; Albanes D; Weinstein SJ; Virtamo J; Kooperberg C; Hohensee C; Rodabough RJ; Cortessis VK; Conti DV; Gago-Dominguez M; Stern MC; Pike MC; Van Den Berg D; Yuan JM; Haiman CA; Cussenot O; Cancel-Tassin G; Roupret M; Comperat E; Porru S; Carta A; Pavanello S; Arici C; Mastrangelo G; Grossman HB; Wang Z; Deng X; Chung CC; Hutchinson A; Burdette L; Wheeler W; Fraumeni J; Chanock SJ; Hewitt SM; Silverman DT; Rothman N; Prokunina-Olsson L
Cancer Res; 2014 Oct; 74(20):5808-18. PubMed ID: 25320178
[TBL] [Abstract][Full Text] [Related]
10. GPNMB
Meng Y; Zhao Q; Sang Y; Liao J; Ye F; Qu S; Nie P; An L; Zhang W; Jiao S; Huang A; Zhou Z; Wei L
EMBO J; 2023 Dec; 42(24):e114060. PubMed ID: 38009297
[TBL] [Abstract][Full Text] [Related]
11. Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells.
Rogers S; Gloss BS; Lee CS; Sergio CM; Dinger ME; Musgrove EA; Burgess A; Caldon CE
Cell Div; 2015; 10():1. PubMed ID: 25741376
[TBL] [Abstract][Full Text] [Related]
12. Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Phan Z; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell DD; ; Serra V; Waring P; Lim E; Caldon CE
NPJ Breast Cancer; 2021 Aug; 7(1):111. PubMed ID: 34465787
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of cyclin-dependent kinase/cyclin-dependent kinase inhibitor expression ratios as biomarkers of locoregional and hematogenous dissemination risks in oral squamous cell carcinoma.
Nagata M; Kurita H; Uematsu K; Ogawa S; Takahashi K; Hoshina H; Takagi R
Mol Clin Oncol; 2015 Sep; 3(5):1007-1013. PubMed ID: 26623041
[TBL] [Abstract][Full Text] [Related]
14. CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination.
Brown VE; Moore SL; Chen M; House N; Ramsden P; Wu HJ; Ribich S; Grassian AR; Choi YJ
NAR Cancer; 2023 Sep; 5(3):zcad039. PubMed ID: 37519629
[No Abstract] [Full Text] [Related]
15. WEE1i-ATRi combination therapy: a promising low-dose treatment for
Goehring L; Huang TT
Cell Rep Med; 2021 Sep; 2(9):100402. PubMed ID: 34622238
[No Abstract] [Full Text] [Related]
16. Copy number variations and protein expression of Cyclin E1 and Epithelial cell transforming sequence 2 genes predict the chemotherapeutic response in patients with serous ovarian carcinoma.
Sarfraz R; Masood A; Zaki S; Shami A; Khaliq S; Naseem N
Pak J Med Sci; 2023; 39(3):835-842. PubMed ID: 37250533
[TBL] [Abstract][Full Text] [Related]
17. Targeting CDK2 in cancer: challenges and opportunities for therapy.
Tadesse S; Anshabo AT; Portman N; Lim E; Tilley W; Caldon CE; Wang S
Drug Discov Today; 2020 Feb; 25(2):406-413. PubMed ID: 31839441
[TBL] [Abstract][Full Text] [Related]
18. Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis.
Krenkel O; Hundertmark J; Abdallah AT; Kohlhepp M; Puengel T; Roth T; Branco DPP; Mossanen JC; Luedde T; Trautwein C; Costa IG; Tacke F
Gut; 2020 Mar; 69(3):551-563. PubMed ID: 31076404
[TBL] [Abstract][Full Text] [Related]
19. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
Esteban-Burgos L; Wang H; Nieto P; Zheng J; Blanco-Aparicio C; Varela C; Gómez-López G; Fernández-García F; Sanclemente M; Guerra C; Drosten M; Galán J; Caleiras E; Martínez-Torrecuadrada J; Fajas L; Peng SB; Santamaría D; Musteanu M; Barbacid M
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24415-24426. PubMed ID: 32913049
[TBL] [Abstract][Full Text] [Related]
20. Ccne1 Overexpression Causes Chromosome Instability in Liver Cells and Liver Tumor Development in Mice.
Aziz K; Limzerwala JF; Sturmlechner I; Hurley E; Zhang C; Jeganathan KB; Nelson G; Bronk S; Fierro Velasco RO; van Deursen EJ; O'Brien DR; Kocher JA; Youssef SA; van Ree JH; de Bruin A; van den Bos H; Spierings DCJ; Foijer F; van de Sluis B; Roberts LR; Gores GJ; Li H; van Deursen JM
Gastroenterology; 2019 Jul; 157(1):210-226.e12. PubMed ID: 30878468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
